20:55:21 EST Sun 28 Nov 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:SRPT from 2020-11-27 to 2021-11-26 - 57 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2021-11-17 08:31U:SRPTNews ReleaseSarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
2021-11-17 08:30U:SRPTNews ReleaseSarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
2021-11-03 16:01U:SRPTNews ReleaseSarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments
2021-11-02 16:30U:SRPTNews ReleaseSarepta Therapeutics to Present at Upcoming Investor Conferences
2021-10-29 18:15U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-10-27 08:30U:SRPTNews ReleaseSarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
2021-10-13 21:15U:SRPTNews ReleaseSarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
2021-10-12 16:04U:SRPTNews ReleaseSarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021
2021-10-12 16:01U:SRPTNews ReleaseSarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
2021-10-11 09:13U:SRPTNews ReleaseSarepta Therapeutics ’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
2021-10-04 16:30U:SRPTNews ReleaseSarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
2021-10-04 07:00U:SRPTNews ReleaseSarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
2021-09-30 19:07U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-09-27 08:30U:SRPTNews ReleaseSarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051  in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
2021-09-14 08:30U:SRPTNews ReleaseSarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
2021-09-07 16:30U:SRPTNews ReleaseSarepta Therapeutics to Present at Upcoming Investor Conferences
2021-09-07 08:30U:SRPTNews ReleaseSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
2021-08-31 17:58U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-08-04 16:05U:SRPTNews ReleaseSarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
2021-08-04 08:30U:SRPTNews ReleaseSarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children ’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
2021-07-30 17:42U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-07-28 08:30U:SRPTNews ReleaseSarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
2021-06-30 18:41U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-06-03 16:30U:SRPTNews ReleaseSarepta Therapeutics to Present at Upcoming Investor Conferences
2021-05-28 18:55U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-05-18 08:51U:SRPTNews ReleaseSarepta Therapeutics ’ Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta ’s Commercial Process Material
2021-05-17 16:05U:SRPTNews ReleaseSarepta Therapeutics to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
2021-05-05 16:05U:SRPTNews ReleaseSarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
2021-05-04 16:30U:SRPTNews ReleaseSarepta Therapeutics to Present at Upcoming Investor Conferences
2021-05-03 08:50U:SRPTNews ReleaseSarepta Therapeutics Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
2021-05-03 08:03U:SRPTNews ReleaseMIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders
2021-04-30 18:45U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-04-30 16:05U:SRPTNews ReleaseSarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
2021-04-28 08:30U:SRPTNews ReleaseSarepta Therapeutics to Announce First Quarter 2021 Financial Results and Recent Corporate Developments on May 5, 2021
2021-04-26 16:05U:SRPTNews ReleaseSarepta Recommends Stockholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
2021-03-23 08:30U:SRPTNews ReleaseSarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
2021-03-18 16:32U:SRPTNews ReleaseSarepta Therapeutics ’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration
2021-03-15 08:30U:SRPTNews ReleaseSarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
2021-03-01 16:05U:SRPTNews ReleaseSarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
2021-02-26 19:13U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-02-25 14:10U:SRPTNews ReleaseSarepta Therapeutics Announces FDA Approval of AMONDYS 45 ™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
2021-02-24 16:30U:SRPTNews ReleaseSarepta Therapeutics to Present at Upcoming Investor Conferences
2021-02-22 08:30U:SRPTNews ReleaseSarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
2021-02-04 20:11U:SRPTNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
2021-02-04 16:30U:SRPTNews ReleaseSarepta Therapeutics Announces Winners of the “Rare Lessons ” Lesson Planning Competition
2021-02-01 17:16U:SRPTNews ReleaseONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
2021-01-29 20:30U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-01-13 08:30U:SRPTNews ReleaseSarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
2021-01-09 13:15U:SRPTNews ReleaseSRPT EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Firm - SRPT
2021-01-08 18:48U:SRPTNews ReleaseSRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws
2021-01-08 08:30U:SRPTNews ReleaseSarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
2021-01-07 16:05U:SRPTNews ReleaseSarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
2020-12-31 18:30U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-12-14 08:30U:SRPTNews ReleaseSarepta Therapeutics Announces Executive Management Changes
2020-12-07 08:55U:SRPTNews ReleaseSarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
2020-12-04 16:05U:SRPTNews ReleaseSarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
2020-11-30 18:05U:SRPTNews ReleaseSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)